Micro-fluidic chip for culturing and treating glioblastoma organoid
By designing organoid cell channels, cooling channels, and metal electrodes on a microfluidic chip, the problems of temperature control and screening speed were solved, enabling efficient glioblastoma organoid culture and treatment, and improving the accuracy of drug screening and the reliability of experimental results.
Patent Information
- Application Number
- CN202520425574.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Utility models(China)
- Current Assignee / Owner
- Filing Date
- 2025-03-12
- Publication Date
- 2026-02-24
- Estimated Expiration
- 2035-03-12
AI Technical Summary
Existing microfluidic chips suffer from poor temperature control and slow screening speed in glioblastoma cell culture and treatment, making it difficult to meet the needs of rapid clinical screening.
An organoid cell flow channel, cooling flow channel, and metal electrode structure were designed to achieve drug injection, screening, electric field application, and temperature control. Through the serpentine design of the cooling flow channel and the precise control of the metal electrode, the in vivo microenvironment was simulated to prevent cell thermal damage and improve screening efficiency.
It achieves high-throughput screening, precisely regulates the cell growth environment, simulates the in vivo microenvironment, improves the accuracy of drug screening and the reliability of experimental results, and prevents cell thermal damage.
Smart Images
Figure CN223936505U_ABST
Abstract
Description
Technical Field
[0001] This utility model relates to the field of microfluidics, specifically to a microfluidic chip for the culture and treatment of glioblastoma organoids. Background Technology
[0002] Glioblastoma is the most malignant type of astrocytic tumor. The tumor is located in the subcortical region, grows infiltratively, often invades several lobes of the brain, and further invades deeper into the brain. It can also spread to the contralateral cerebral hemisphere via the corpus callosum.
[0003] Treatment options for glioblastoma include medication, surgery, and radiotherapy. Commonly used medications include mannitol, glucocorticoids, and sodium valproate. Mannitol can rapidly dehydrate and reduce intracranial pressure, making it suitable for patients with cerebral edema. Glucocorticoids have anti-inflammatory and immunosuppressive effects; high-dose use of glucocorticoids is not recommended for pregnancy, and pregnant women should use them with caution. A common adverse reaction is central obesity. Sodium valproate is a broad-spectrum antiepileptic drug suitable for patients with seizures; common adverse reactions include diarrhea, indigestion, nausea, vomiting, and gastrointestinal spasms. Surgical treatment can utilize techniques such as ultrasound, subcortical electrical stimulation, neuronavigation, fluorescence imaging, and intraoperative MRI to achieve complete tumor resection. However, for patients with poor baseline health or tumors located in critical functional areas, a complete resection strategy at the expense of quality of life is not scientifically sound. Radiotherapy often uses Gamma Knife or linear accelerators to precisely target the tumor and reduce damage to surrounding normal tissues; however, long-term radiotherapy may lead to cognitive decline. In addition, tumor-treating fields (TTFields) is a novel treatment modality that has been developed and clinically proven to inhibit gliomas in the last decade. TTFields is a therapy administered via a portable, non-invasive medical device. Its principle is to use a low-intensity, mid-frequency (200kHz) alternating electric field to act on the microtubules of proliferating cancer cells, interfering with tumor cell mitosis, causing apoptosis in affected cancer cells, and inhibiting tumor growth. However, significant heterogeneity has been observed in clinical practice; some patients benefit significantly, while others exhibit electric field resistance.
[0004] Therefore, in the treatment of glioblastoma, it is necessary to test the effects of a large number of different chemicals and applied electric fields on cells to determine their sensitivity to drug or physical therapy. High-throughput microfluidic chips can be used to quickly screen tumor cells for sensitivity. The microchannel size of microfluidic chip design (typically 10–100 μm) is on the same order of magnitude as the size of typical mammalian cells (10–20 μm), and heat and mass transfer are faster at the microscale, providing a favorable environment for cell growth research. At the same time, microfluidic chips can meet the needs of high-throughput cell analysis.
[0005] However, existing microfluidic chips used for three-dimensional cell culture and microenvironment simulation generally suffer from problems such as poor temperature control and slow screening speed, making it difficult to meet the needs of rapid clinical screening. Utility Model Content
[0006] To address the shortcomings of existing technologies, this invention provides a microfluidic chip for the culture and treatment of glioblastoma organoids. By employing a structural design that incorporates organoid cell channels, cooling channels, and metal electrodes, it enables the introduction, screening, application of electric fields, and temperature control of drugs for organoid culture and treatment.
[0007] To achieve the above objectives, this utility model provides the following technical solution:
[0008] A microfluidic chip for glioblastoma organoid culture and treatment includes a substrate. Organoid cell channels and cooling channels are respectively formed within the substrate. Multiple sample inlets and multiple sample outlets are respectively formed at both ends of the organoid cell channels. The cooling channels are arranged in a serpentine bend and are located below the organoid cell channels. A coolant inlet and a coolant outlet are respectively formed at both ends of the cooling channels. A first metal electrode and a second metal electrode are fixedly mounted on the substrate. The first and second metal electrodes are respectively located on opposite sides of the organoid cell channels. Both the first and second metal electrodes are close to the sample outlets of the organoid cell channels. The first and second metal electrodes are connected to an external power source via wires.
[0009] Preferably, the substrate includes an upper substrate and a lower substrate, which are tightly bonded and fixed together. The upper substrate has organoid cell flow channels, and the lower substrate has cooling channels.
[0010] Preferably, the organoid cell flow channel includes seven parallel main cell channels and a first, second, and third parallel inlet channel. The first, second, and third inlet channels are all perpendicular to the main cell channels. The first inlet channel has a first inlet port at its front end, and the rear ends of the first, second, and third inlet channels have a second, third, and fourth inlet port, respectively. The cooling channel is located below the main cell channels.
[0011] The first and second injection channels are connected by four parallel first connecting channels, and the second and third injection channels are connected by five parallel second connecting channels. The first and second connecting channels are staggered. The left end of the main cell channel furthest from the fourth injection port is connected to the second injection channel, and the left ends of the other six main cell channels are all connected to the third injection channel. The second connecting channels are staggered with the six main cell channels. Each of the seven main cell channels has an outlet at its right end.
[0012] Preferably, the first metal electrode and the second metal electrode are deposited on the substrate surface using a magnetron sputtering method.
[0013] Preferably, the substrate material is polydimethylsiloxane.
[0014] This utility model also discloses a method for preparing a microfluidic chip for glioblastoma organoid culture and treatment, comprising the following steps:
[0015] Step S1: Mixing the adhesive; mix polydimethylsiloxane with the crosslinking agent in a certain proportion; and stir and mix evenly using a vacuum degassing mixer to remove air bubbles;
[0016] Step S2: Modification; Place the mixture obtained in step S1 into a vat, add 1-2 drops of modifier and spread evenly, ensuring that the modifier completely covers the surface of the mixture;
[0017] Step S3: Pour the adhesive; First, lay the tin foil flat in the dish, place the silicon wafer mold in it, then gently press the silicon wafer mold firmly and pour in the mixture obtained in step S2, ensuring that the filling is uniform and free of air bubbles;
[0018] Step S4: Place the dish after pouring the glue in step S3 into a constant temperature oven, set the temperature to 85℃, and bake for 25-60 minutes. After the mixture has completely solidified, remove it and let it cool.
[0019] Step S5: Demolding; Gently peel off the tin foil to separate the cured mixture from the silicon wafer mold, obtaining the cured microfluidic chip substrate; Clean to remove surface residues from the microfluidic chip substrate;
[0020] Step S6: Cutting; Use a cutting tool to cut the cured microfluidic chip substrate into the required shape and size according to the design drawings, ensuring that the edges are smooth and burr-free;
[0021] Step S7: Characterize cell flow channels and cooling flow channels; using photolithography, the required organoid cell flow channels and cooling flow channels, as well as the corresponding interconnection structures, are characterized on the surface of the microfluidic chip substrate using a photomask to ensure that the flow channels are smooth and unobstructed.
[0022] Step S8: Drilling; According to the design requirements, drill holes on the microfluidic chip substrate using a hole puncher. The positions of the holes correspond to the sample inlets and outlets of the organoid cell flow channels, and the coolant inlets and outlets of the cooling flow channels, respectively.
[0023] Step S9: Cleaning; Use a lint-free cloth and cleaning solution to thoroughly remove any residue from the surface and holes of the microfluidic chip substrate to ensure there are no impurities;
[0024] Step S10: Microscopic inspection; Use a microscope to observe the surface and internal structure of the microfluidic chip substrate to confirm that there are no defects or impurities.
[0025] Step S11: Electrode deposition; using magnetron sputtering technology, the first metal electrode and the second metal electrode are uniformly deposited on the substrate surface to ensure good conductivity.
[0026] Preferably, the ratio of polydimethylsiloxane to crosslinking agent is 10:1.
[0027] Preferably, in step S2, the modifier is a silane coupling agent with excellent biocompatibility.
[0028] Furthermore, in step S6, two substrates are obtained by cutting. In step S7, photolithography is used to etch organoid cell channels on one substrate and cooling channels on the other substrate using a photomask. The substrate with the etched organoid cell channels is then tightly bonded and fixed to the upper side of the substrate with the etched cooling channels by thermo-press bonding or adhesive bonding.
[0029] This invention provides a microfluidic chip and its preparation method for glioblastoma organoid culture and treatment, which has the following beneficial effects: By introducing the cells to be cultured and the protective solution into one inlet of the organoid cell channel, and introducing the therapeutic drug solution to be screened into the other inlets, multiple outlets can be used to obtain cell-drug mixtures with different concentration gradients, achieving high-throughput screening and enabling evaluation of drug efficacy. Furthermore, by applying an electric field of a certain intensity to the position of the organoid cell channel near the outlet using the first and second metal electrodes, cell growth and differentiation can be promoted, thereby affecting the growth direction and distribution of cells. By real-time monitoring of current intensity and cell response, the culture environment of the organoid can be precisely controlled. This allows for fine control of cell growth and differentiation on the microfluidic chip, thereby simulating the in vivo microenvironment and increasing the biomimeticity of organoid culture. Finally, by adjusting the temperature of the coolant in the cooling channel, the temperature of the cells to be cultured and the protective solution within the organoid cell channel can be effectively controlled, thus simulating the internal environment of the human body. When an electric current is applied to the organoid cell channels to stimulate the cells, the cooling channels prevent thermal damage to the cells caused by excessive temperature. Simultaneously, the flow of coolant helps stabilize the temperature, providing a suitable growth environment for the cells. Attached Figure Description
[0030] To more clearly illustrate the technical solutions in this utility model or the prior art, the accompanying drawings used in the description of the prior art will be briefly introduced below.
[0031] Figure 1 A schematic diagram of the structure of this utility model;
[0032] Figure 2 A schematic diagram of the organoid cell flow channel in this utility model;
[0033] Figure 3 A schematic diagram of the cooling channel structure in this utility model;
[0034] Explanation of the labels in the diagram:
[0035] 1. Substrate; 101. Upper substrate; 102. Lower substrate; 2. Organoid cell flow channel; 21. Main cell flow channel; 22. First inlet flow channel; 23. Second inlet flow channel; 24. Third inlet flow channel; 25. First connecting flow channel; 26. Second connecting flow channel; 27. First inlet; 28. Second inlet; 29. Third inlet; 210. Fourth inlet; 3. Cooling flow channel; 31. Coolant inlet; 32. Coolant outlet; 41. First metal electrode; 42. Second metal electrode. Detailed Implementation
[0036] To make the objectives, technical solutions, and advantages of this utility model clearer, the technical solutions of this utility model will be clearly and completely described below with reference to the accompanying drawings.
[0037] Example 1, as Figures 1 to 3 As shown, a microfluidic chip for glioblastoma organoid culture and treatment includes a substrate 1. Organoid cell channels 2 and cooling channels 3 are respectively formed within the substrate 1. Multiple inlets and outlets are respectively formed at both ends of the organoid cell channels 2. The cooling channels 3 are arranged in a serpentine bend and are located below the organoid cell channels 2. Specifically, in this embodiment, the substrate 1 includes an upper substrate 101 and a lower substrate 102. Organoid cell channels 2 are formed within the upper substrate 101, and cooling channels 3 are formed within the lower substrate 102. The upper substrate 101 and the lower substrate 102 are then tightly bonded and fixed together by thermocompression bonding or adhesive bonding.
[0038] A coolant inlet 31 and a coolant outlet 32 are respectively opened at both ends of the cooling channel 3; a first metal electrode 41 and a second metal electrode 42 are fixedly installed on the substrate 1. The first metal electrode 41 and the second metal electrode 42 are respectively located on both sides of the organoid cell channel 2. The first metal electrode 41 and the second metal electrode 42 are close to the sample outlet of the organoid cell channel 2. The first metal electrode 41 and the second metal electrode 42 are connected to an external power source through wires.
[0039] Working principle:
[0040] During drug screening, cells to be cultured and protective solution can be introduced into one inlet of the organoid cell channel 2, while the therapeutic drug solution to be screened can be introduced into the other inlets. Therefore, multiple outlets can be used to obtain cell-drug mixtures with different concentration gradients, achieving high-throughput screening and enabling the evaluation of drug efficacy. Simultaneously, while introducing cells and protective solution into the organoid cell channel 2, an electric field of a certain intensity is applied to the area near the outlet of the organoid cell channel 2 using the first metal electrode 41 and the second metal electrode 42. This electric field promotes cell growth and differentiation, thereby influencing the growth direction and distribution of cells. By monitoring the current intensity and cell response in real time, the culture environment of the organoids can be precisely controlled. This allows for precise control of cell growth and differentiation on the microfluidic chip, simulating the in vivo microenvironment and increasing the biomimetic nature of organoid culture. This not only helps in evaluating the effectiveness of therapeutic drugs but also provides a powerful tool for a deeper understanding of cellular pathological processes. Furthermore, during treatment, by adjusting the temperature of the coolant within the cooling channel 3, the temperature of the cells to be cultured and the protective solution within the organoid cell channel 2 can be effectively controlled, thus simulating the internal environment of the human body. When cells in the organoid cell channel 2 are stimulated by electric current, the cooling channel 3 prevents thermal damage to the cells caused by excessive temperature. Simultaneously, the flow of coolant helps stabilize the temperature, providing a suitable growth environment for the cells. In addition, the serpentine design of the cooling channel 3 increases the contact area between the coolant and the chip substrate, improving cooling efficiency. Since precise temperature control is crucial for cell viability, the serpentine design of the cooling channel 3 not only optimizes cooling efficiency but also effectively reduces heat loss without increasing volume excessively. When experiments require long-term continuous operation, this design ensures that the temperature within the organoid cell channel 2 remains within a stable and suitable range, guaranteeing the reliability and repeatability of experimental results.
[0041] Example 2, as a further preferred embodiment of Example 1, the organoid cell flow channel 2 includes seven parallel main cell channels 21 and a first inlet channel 22, a second inlet channel 23, and a third inlet channel 24 arranged in parallel. The first inlet channel 22, the second inlet channel 23, and the third inlet channel 24 are all arranged perpendicular to the main cell channels 21. The front end of the first inlet channel 22 is provided with a first inlet port 27, and the rear ends of the first inlet channel 22, the second inlet channel 23, and the third inlet channel 24 are respectively provided with a second inlet port 28, a third inlet port 29, and a fourth inlet port 210. The cooling channel 3 is located below the main cell channels 21.
[0042] The first sample inlet channel 22 and the second sample inlet channel 23 are connected by four parallel first connecting channels 25. The second sample inlet channel 23 and the third sample inlet channel 24 are connected by five parallel second connecting channels 26. The first connecting channels 25 and the second connecting channels 26 are staggered. The left end of the main cell channel 21 away from the fourth sample inlet 210 is connected to the second sample inlet channel 23. The left ends of the other six main cell channels 21 are all connected to the third sample inlet channel 24. The second connecting channels 26 are staggered with the six main cell channels 21 respectively. The right ends of the seven main cell channels 21 are all provided with sample outlets.
[0043] Therefore, during use, the cells to be cultured and the protective solution can be introduced into the first inlet 27, and the therapeutic drugs to be screened can be introduced into the second inlet 28, the third inlet 29, and the fourth inlet 210, respectively. Through the interleaved paths of the first connecting channel 25 and the second connecting channel 26, and the interleaved paths of the second connecting channel 26 and the six main cell channels 21, the drugs can pass through the main cell channels 21 along specific paths and come into contact with the cells, thus obtaining various cell-drug mixtures with different concentration gradients. This allows the cells to exhibit different responses under different drug concentrations, enabling researchers to simultaneously compare and evaluate the effects of multiple drugs. This helps in studying the effects of drugs on cell activity and screening for the optimal treatment regimen.
[0044] In Example 3, as a further preferred embodiment of Example 1, the first metal electrode 41 and the second metal electrode 42 are deposited on the surface of the substrate 1 using magnetron sputtering. By employing magnetron sputtering to deposit the first metal electrode 41 and the second metal electrode 42 onto the surface of the substrate 1, the thickness and uniformity of the first metal electrode 41 and the second metal electrode 42 are effectively ensured to meet experimental requirements. This, in turn, ensures that the current can pass uniformly through the main cell channel 21. Additionally, in this embodiment, the first metal electrode 41 and the second metal electrode 42 can also be connected to a control unit (not shown) via a circuit. The voltage between the first metal electrode 41 and the second metal electrode 42 can be adjusted by the control unit, allowing precise control of the electric field strength in the organoid cell channel 2, thereby affecting the absorption and distribution of drugs in the cells and enhancing the accuracy of drug screening. Utilizing electric field modulation technology to guide cell growth in specific regions and promote more effective drug-cell binding improves experimental efficiency and the accuracy of results. This method can simulate the in vivo environment, providing more realistic biological response data for drug screening.
[0045] Example 4, as a further preferred embodiment of Example 1, uses polydimethylsiloxane (PDS) as the substrate material, which has good biocompatibility. By using PDS as the substrate 1, it achieves good biocompatibility and flexibility. This material not only simulates the microenvironment for cell survival but also facilitates observation and recording of cell growth. Furthermore, the PDS substrate has a certain degree of transparency, which also facilitates observation of cell growth and related manipulations. Moreover, PDS is easy to process, thus facilitating the fabrication of organoid cell channels 2 and cooling channels 3, which is helpful for studying cell-cell and cell-drug interactions. By precisely controlling the cell growth environment, researchers can more accurately simulate the in vivo drug action mechanism, thereby achieving efficient drug screening and evaluation in vitro.
[0046] Example 5: This utility model also discloses a method for preparing a microfluidic chip for glioblastoma organoid culture and treatment, characterized by the following steps:
[0047] Step S1: Mixing the adhesive; mix polydimethylsiloxane with the crosslinking agent at a ratio of 10:1; and stir and mix evenly using a vacuum degassing mixer to remove air bubbles;
[0048] Step S2: Modification; Place the mixture obtained in step S1 into a volatilization tank, add 1-2 drops of modifying agent and spread evenly, ensuring the modifying agent completely covers the surface of the mixture; wherein, the modifying agent is a silane coupling agent with excellent biocompatibility. Specifically, methylchlorosilane can be used as the modifying agent; methylchlorosilane can not only effectively improve the hydrophilicity of the polydimethylsiloxane surface, but also promote cell adhesion and growth on the chip. This effectively ensures the stable culture of glioblastoma organoids on the microfluidic chip.
[0049] Step S3: Pour the adhesive; First, lay the tin foil flat in the dish, place the silicon wafer mold in it, then gently press the silicon wafer mold firmly and pour in the mixture obtained in step S2, ensuring that the filling is uniform and free of air bubbles;
[0050] Step S4: Place the dish after pouring the glue in step S3 into a constant temperature oven, set the temperature to 85℃, bake for 30 minutes, and remove and cool after the mixture has completely solidified.
[0051] Step S5: Demolding; Gently peel off the tin foil to separate the cured mixture from the silicon wafer mold, obtaining the cured microfluidic chip substrate; Clean to remove surface residues from the microfluidic chip substrate;
[0052] Step S6: Cutting; Use a cutting tool to cut the cured microfluidic chip substrate into the required shape and size according to the design drawings, ensuring that the edges are smooth and burr-free;
[0053] Step S7: Delineate cell flow channels and cooling flow channels; Using photolithography, the required organoid cell flow channels, cooling flow channels, and corresponding connecting structures are delineated on the surface of the microfluidic chip substrate using a photomask, ensuring that the flow channels are smooth and unobstructed; In this embodiment, two substrates obtained through the above steps can be used as the upper substrate and the lower substrate, respectively. The required organoid cell flow channels and corresponding connecting structures, cooling flow channels, and corresponding connecting structures are delineated on the surfaces of the upper substrate and the lower substrate using a photomask, ensuring that the flow channels are smooth and unobstructed. The upper substrate and the lower substrate are then tightly bonded and fixed together by thermo-press bonding or adhesive bonding to obtain a complete microfluidic chip substrate;
[0054] Step S8: Drilling; According to the design requirements, drill holes on the microfluidic chip substrate using a hole puncher. The positions of the holes correspond to the sample inlets and outlets of the organoid cell flow channels, and the coolant inlets and outlets of the cooling flow channels, respectively.
[0055] Step S9: Cleaning; Use a lint-free cloth and cleaning solution to thoroughly remove any residue from the surface and holes of the microfluidic chip substrate to ensure there are no impurities;
[0056] Step S10: Microscopic inspection; Use a microscope to observe the surface and internal structure of the microfluidic chip substrate to confirm that there are no defects or impurities.
[0057] Step S11: Electrode deposition; using magnetron sputtering technology, the first metal electrode and the second metal electrode are uniformly deposited on the substrate surface to ensure good conductivity.
[0058] Specifically, the control unit, photomask, and photolithography technology used in this utility model all adopt well-known technical solutions in the prior art, and will not be described in detail here.
[0059] A microfluidic chip for glioblastoma organoid culture and treatment was prepared using the above method. This microfluidic chip exhibits excellent cell adhesion, microenvironment simulation capabilities, and stable operational performance. Under in vitro simulated conditions, it can support the long-term growth and differentiation of glioblastoma organoids, providing a powerful tool for glioblastoma organoid culture, drug screening, and pathological research.
[0060] The above embodiments are only used to illustrate the technical solutions of this utility model, and are not intended to limit it. Although this utility model has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some of the technical features. Such modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the spirit and scope of the technical solutions of the embodiments of this utility model.
Claims
1. A microfluidic chip for glioblastoma organoid culture and treatment, characterized in that: The system includes a substrate (1), in which an organoid cell flow channel (2) and a cooling flow channel (3) are respectively formed. Multiple sample inlets and multiple sample outlets are respectively formed at both ends of the organoid cell flow channel (2). The cooling flow channel (3) is arranged in a serpentine bend and is located below the organoid cell flow channel (2). A coolant inlet (31) and a coolant outlet (32) are respectively formed at both ends of the cooling flow channel (3). A first metal electrode (41) and a second metal electrode (42) are fixedly installed on the substrate (1). The first metal electrode (41) and the second metal electrode (42) are respectively located on both sides of the organoid cell flow channel (2). The first metal electrode (41) and the second metal electrode (42) are both close to the sample outlet of the organoid cell flow channel (2). The first metal electrode (41) and the second metal electrode (42) are connected to an external power source through wires.
2. The microfluidic chip for glioblastoma organoid culture and treatment according to claim 1, characterized in that: The substrate (1) includes an upper substrate (101) and a lower substrate (102), which are tightly bonded and fixed together. An organoid cell flow channel (2) is formed in the upper substrate (101), and a cooling flow channel (3) is formed in the lower substrate (102).
3. The microfluidic chip for glioblastoma organoid culture and treatment according to claim 1, characterized in that: The organoid cell flow channel (2) includes seven parallel main cell channels (21) and a first inlet channel (22), a second inlet channel (23), and a third inlet channel (24) arranged in parallel. The first inlet channel (22), the second inlet channel (23), and the third inlet channel (24) are all arranged perpendicular to the main cell channels (21). The front end of the first inlet channel (22) is provided with a first inlet port (27), and the rear end of the first inlet channel (22), the rear end of the second inlet channel (23), and the rear end of the third inlet channel (24) are respectively provided with a second inlet port (28), a third inlet port (29), and a fourth inlet port (210). The cooling channel (3) is located below the main cell channels (21). The first injection channel (22) and the second injection channel (23) are connected by four parallel first connecting channels (25), and the second injection channel (23) and the third injection channel (24) are connected by five parallel second connecting channels (26). The first connecting channels (25) and the second connecting channels (26) are staggered. The left end of one main cell channel (21) away from the fourth injection port (210) is connected to the second injection channel (23), and the left ends of the other six main cell channels (21) are all connected to the third injection channel (24). The second connecting channels (26) are staggered with the six main cell channels (21) respectively. The right end of each of the seven main cell channels (21) is provided with an outlet.
4. The microfluidic chip for glioblastoma organoid culture and treatment according to claim 1, characterized in that: The first metal electrode (41) and the second metal electrode (42) are deposited on the surface of the substrate (1) by magnetron sputtering.
5. A microfluidic chip for glioblastoma organoid culture and treatment according to claim 1, characterized in that: The substrate (1) is made of polydimethylsiloxane.